Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi & Nupur Greene. (2023) Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. ClinicoEconomics and Outcomes Research 15, pages 361-373.
Read now
Read now
Crystal Watson, Christine Prosser, Sebastian Braun, Pamela B Landsman-Blumberg, Erika Gleissner & Sarah Naoshy. (2017) Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany. ClinicoEconomics and Outcomes Research 9, pages 85-97.
Read now
Read now
Emily Nash Smyth, Ilaria Conti, James E. Wooldridge, Lee Bowman, Li Li, David R. Nelson & Daniel E. Ball. (2016) Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma. Journal of Medical Economics 19:5, pages 477-486.
Read now
Read now
Niklas Bergvall, Raquel Lahoz, Tracy Reynolds & Jonathan R. Korn. (2014) Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Current Medical Research and Opinion 30:8, pages 1461-1471.
Read now
Read now
Articles from other publishers (8)
Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi & Nupur Greene. (2023) Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA. Journal of Comparative Effectiveness Research 12:1.
Crossref
Crossref
Wen Zhu, Xiaoyu Tang, Rock A. Heyman, Tianxi Cai, Kangho Suh, John D. Seeger & Zongqi Xia. (2022) Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010–2019. Neurology and Therapy 11:3, pages 1147-1165.
Crossref
Crossref
Huah Shin Ng, Feng Zhu, Elaine Kingwell, Yinshan Zhao, Shenzhen Yao, Okechukwu Ekuma, Lawrence W Svenson, Charity Evans, John D Fisk, Ruth Ann Marrie & Helen Tremlett. (2021) Disease-modifying drugs for multiple sclerosis and subsequent health service use. Multiple Sclerosis Journal 28:4, pages 583-596.
Crossref
Crossref
Huah Shin Ng, Jonas Graf, Feng Zhu, Elaine Kingwell, Orhan Aktas, Philipp Albrecht, Hans-Peter Hartung, Sven G. Meuth, Charity Evans, John D. Fisk, Ruth Ann Marrie, Yinshan Zhao & Helen Tremlett. (2022) Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. Frontiers in Immunology 12.
Crossref
Crossref
Jacqueline Nicholas, Aaron Boster, Ning Wu, Wei-Shi Yeh, Monica Fay, Jon Kendter, Ming-Yi Huang & Andrew Lee. (2017) Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data. PharmacoEconomics - Open 2:1, pages 31-41.
Crossref
Crossref
Alex Y. Chen, Amy O. Chonghasawat & Kevin L. Leadholm. (2017) Multiple sclerosis: Frequency, cost, and economic burden in the United States. Journal of Clinical Neuroscience 45, pages 180-186.
Crossref
Crossref
Tjalf Ziemssen, Jan Hillert & Helmut Butzkueven. (2016) The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine 14:1.
Crossref
Crossref
Barbara H. Johnson, Machaon M. Bonafede & Crystal Watson. (2015) Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. CNS Drugs 29:6, pages 503-510.
Crossref
Crossref